Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients.

摘要: Allogeneic hematopoietic stem cell transplantation is often used to treat hematologic malignancies. The efficacy of this procedure due both myeloablative conditioning and graft-versus-leukemia (GVL). However, the disadvantages allogeneic include graft-versus-host disease (GVHD), relapse from original tumor, patient susceptibility opportunistic infections. Lately, has been developed solid tumors, with expectation that graft-versus-tumor (GVT), like GVL, will have a significant anti-tumor effect. This effect demonstrated in renal carcinomas, less evidence breast cancers. Five patients malignant ovarian tumors resistant chemotherapy underwent transplantation, four bone marrow, one peripheral blood cells. All donors were HLA-identical siblings. One received regimen, while other non-myeloablative regimen. Two donor lymphocyte infusions (DLI). Four presented acute or chronic GVHD associated tumor regression at least 50%. These regressions measured by CA-125 levels CT scans. fifth died rapid progression just after transplantation. Of survivors, three regimen which did not seem reduce treatment effectiveness. While it toxicity, these 127 days. DLI was administered two patients. seemed promote able control for had no apparent on other. Allograft cells might be interest cancer. results also suggest may an effective immunotherapy, although doses timing need determined. number cases small, however, clinical experience larger scale required determine real graft versus cancerous